BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 20206067)

  • 1. Exploring new indications for statins beyond atherosclerosis: Successes and setbacks.
    Waters DD
    J Cardiol; 2010 Mar; 55(2):155-62. PubMed ID: 20206067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
    Mora S; Ridker PM
    Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).
    Ridker PM; MacFadyen JG; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
    Circ Cardiovasc Qual Outcomes; 2009 Nov; 2(6):616-23. PubMed ID: 20031900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering.
    Pedersen TR
    Am J Cardiovasc Drugs; 2010; 10 Suppl 1():10-7. PubMed ID: 21391729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?
    Fabbri G; Maggioni AP
    Adv Ther; 2009 May; 26(5):469-87. PubMed ID: 19444394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Statins in aortic stenosis].
    Dejanović J; Ivanov I
    Med Pregl; 2009; 62 Suppl 3():101-4. PubMed ID: 19702126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure).
    Cleland JG; McMurray JJ; Kjekshus J; Cornel JH; Dunselman P; Fonseca C; Hjalmarson A; Korewicki J; Lindberg M; Ranjith N; van Veldhuisen DJ; Waagstein F; Wedel H; Wikstrand J;
    J Am Coll Cardiol; 2009 Nov; 54(20):1850-9. PubMed ID: 19892235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statins and stroke prevention.
    Paciaroni M; Hennerici M; Agnelli G; Bogousslavsky J
    Cerebrovasc Dis; 2007; 24(2-3):170-82. PubMed ID: 17596685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting benefit from statins by C-reactive protein, LDL-cholesterol or absolute cardiovascular risk.
    Stewart RA
    Future Cardiol; 2009 May; 5(3):231-6. PubMed ID: 19656039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [To treat or not to treat with statins patients with chronic heart failure?].
    Hradec J
    Vnitr Lek; 2009 Sep; 55(9):802-7. PubMed ID: 19785380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protecting the heart: a practical review of the statin studies.
    Ong HT
    MedGenMed; 2002 Dec; 4(4):1. PubMed ID: 12817199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atorvastatin: gold standard for prophylaxis of myocardial ischemia and stroke - comparison of the clinical benefit of statins on the basis of randomized controlled endpoint studies.
    Gresser U; Gathof BS
    Eur J Med Res; 2004 Jan; 9(1):1-17. PubMed ID: 14766335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE; Feely J; Sigurdsson EL;
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statins and LDL-cholesterol lowering: an overview.
    Stroes E
    Curr Med Res Opin; 2005; 21 Suppl 6():S9-16. PubMed ID: 16138936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care.
    Harley CR; Gandhi SK; Heien H; McDonough K; Nelson SP
    Expert Opin Pharmacother; 2008 Apr; 9(5):669-76. PubMed ID: 18345946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [No reason to start treatment with statins in patients with moderate to severe heart failure].
    Stalenhoef AF
    Ned Tijdschr Geneeskd; 2008 Mar; 152(9):486-8. PubMed ID: 18389878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Two decades of statin trials: clinical, intermediate and surrogate endpoints].
    Fabbri G; Di Pasquale G; Greco C; Musuraca AC; Tavazzi L
    G Ital Cardiol (Rome); 2009 Dec; 10(11-12 Suppl 3):18S-24S. PubMed ID: 21298857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
    Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
    J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aortic sclerosis, aortic stenosis and lipid-lowering therapy.
    Rosenhek R; Baumgartner H
    Expert Rev Cardiovasc Ther; 2008 Mar; 6(3):385-90. PubMed ID: 18327997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.